Clinical Trial

A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-30; most recent amendment 2026-06-28.
Status change: Recruiting → Active, Not Recruiting 2026-06-28
Status change: Not Yet Recruiting → Recruiting 2025-06-11
Trial Details
NCT Number NCT07010120
Lead Sponsor West China Hospital
Conditions HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy
Enrollment 29 participants
Start Date 2025-06-10
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-01